• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by InspireMD Inc. (Amendment)

    2/11/22 5:04:24 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care
    Get the next $NSPR alert in real time by email
    SC 13G/A 1 sc13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 2)*
     

     
    InspireMD, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.0001 per share.
     
     
    (Title of Class of Securities)
     

     
    45779A846
     
     
    (CUSIP Number)
     

     
    December 31, 2021
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Macro Fund, LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    177,333
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    177,333
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    177,333(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    2.1%
     
    12
    Type of Reporting Person (See Instructions)
    PN
     
    (1) Consists of warrants to purchase 177,333 shares of common stock (“Warrants”).


    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners LLC
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    177,333
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    177,333
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
     177,333(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    2.1%
     
    12
    Type of Reporting Person (See Instructions)
    OO
     
    (1) Consists of 177,333 Warrants.



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    177,333
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    177,333
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    177,333(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    2.1%
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     
    (1) Consists of 177,333 Warrants.


    Item 1.
    (a)
    Name of Issuer
     
     
    InspireMD, Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    4 Menorat Hamaor St.
    Tel Aviv, Isreal 6744832
     

    Item 2.
    (a)
    Name of Person Filing
     
     
    This amendment is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •  Lind Global Macro Fund LP, a Delaware limited partnership;
    •  Lind Global Partners LLC, a Delaware limited liability company; and
    •  Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners LLC, the general partner of Lind Global Macro Fund, LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Macro Fund, LP.
     
    Jeff Easton, the managing member of Lind Global Partners LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Macro Fund, LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
    Common Stock, par value $0.0001 per share
     
    (e)
    CUSIP Number
     
     
    45779A846


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ý.
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not Applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 11, 2022
         
    LIND GLOBAL MACRO FUND, LP
       
    By:
     
    Lind Global Partners LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    /s/ Jeff Easton
    Jeff Easton






















    Get the next $NSPR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NSPR

    DatePrice TargetRatingAnalyst
    2/2/2026$6.00Buy
    Maxim Group
    More analyst ratings

    $NSPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on InspireMD with a new price target

    Maxim Group initiated coverage of InspireMD with a rating of Buy and set a new price target of $6.00

    2/2/26 7:53:56 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Gleason Shane Thomas sold $99,331 worth of shares (61,194 units at $1.62), decreasing direct ownership by 5% to 1,139,177 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    2/2/26 5:01:41 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Ward Scott R. was granted 88,053 shares, increasing direct ownership by 147% to 147,846 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    1/16/26 6:12:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Chief Operating Officer Tommasoli Andrea was granted 226,695 shares, increasing direct ownership by 31% to 954,389 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    1/16/26 6:11:38 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the "Inducement Grants") outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted u

    1/20/26 9:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

    The CGuard® Prime Carotid Stent System demonstrated the lowest 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid stenting (CAS) MIAMI, Jan. 12, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that results from the Company's C-GUARDIANS pivotal trial have now been published in the Journal of the American College of Cardiology (JACC). The data demonstrate the safety and efficacy of carotid artery stenting (CAS) with the Company's MicroNet™ covered stent in patients with asymptomatic carotid stenosis. As shown at

    1/12/26 9:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

    MIAMI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, welcomes the recent presentation and publication of CREST-2 data which demonstrated positive clinical outcomes for carotid artery stenting (CAS) for patients with asymptomatic carotid stenosis. CREST-2 data was shown at The Society of Vascular and Interventional Neurology (SVIN) Annual Meeting and the Vascular and Endovascular Issues Techniques and Horizons (VEITH) Symposium on November 21, 2025. In conjunction, the CREST-2 study was published in the New England Journal of Medicine. CREST-2 showed that, amo

    11/24/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    SEC Filings

    View All

    InspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - InspireMD, Inc. (0001433607) (Filer)

    12/19/25 4:15:42 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by InspireMD Inc.

    S-8 - InspireMD, Inc. (0001433607) (Filer)

    11/18/25 4:15:40 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by InspireMD Inc.

    SCHEDULE 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/25 6:12:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Stuka Paul bought $9,182 worth of shares (5,073 units at $1.81), increasing direct ownership by 1% to 391,628 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/11/25 4:05:09 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $9,436 worth of shares (5,073 units at $1.86), increasing direct ownership by 1% to 388,918 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/8/25 4:05:12 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Director Stuka Paul bought $18,740 worth of shares (10,130 units at $1.85), increasing direct ownership by 3% to 383,845 units (SEC Form 4)

    4 - InspireMD, Inc. (0001433607) (Issuer)

    12/5/25 4:05:02 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Names Peter A. Soukas, M.D., as Chief Medical Officer

    MIAMI, Nov. 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Peter A. Soukas, M.D., as Chief Medical Officer to advance its mission to deliver best-in-class tools for carotid intervention. "We are thrilled to have Dr. Soukas join InspireMD to help lead our clinical and medical organization with strategy and oversight at this pivotal time for the Company," said Marvin Slosman, Chief Executive Officer of InspireMD. "His expertise and clinical practice focus in carotid intervention and peripheral vascular disease offer valuable insight

    11/3/25 7:30:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

    MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experience in medical technology with a successful track record of scaling commercial operations and creating shareholder value through market leadership and successful exit transactions. "We are thrilled to welcome Ray to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "We expect to benefit greatly from his vast insights and experience. His

    7/31/25 8:31:00 AM ET
    $KMTS
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by InspireMD Inc.

    SC 13G - InspireMD, Inc. (0001433607) (Subject)

    12/4/24 4:31:06 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    11/14/24 6:35:20 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by InspireMD Inc.

    SC 13G/A - InspireMD, Inc. (0001433607) (Subject)

    10/28/24 4:02:11 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    $NSPR
    Financials

    Live finance-specific insights

    View All

    InspireMD Reports Third Quarter 2025 Financial Results

    MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the third quarter and nine months ended September 30, 2025. Recent Business Highlights: Initiated U.S. commercial launch of the CGuard Prime carotid stent systemCompleted over 100 U.S. carotid procedures across leading hospitalsStrengthened leadership team with the appointment of Peter A. Soukas, M.D., as Chief Medical OfficerAppointed Dan Dearen to the Board of Directors as Audit Committee Chairman bringing valuable experience to InspireMD Marvin Slosma

    11/4/25 7:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD to Announce Third Quarter 2025 Financial Results

    MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its third quarter 2025 financial results on Tuesday, November 4, 2025. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. Interested parties may access the live earnings call via telephone by dialing 1-800-579-2543 for domestic callers or 1-785-424-1789 for international callers. The live webinar may be accessed by visiting InspireMD's website or by registering below. A replay of the webin

    10/21/25 4:05:00 PM ET
    $NSPR
    Medical/Dental Instruments
    Health Care

    InspireMD Reports Second Quarter 2025 Financial Results

    --- Management to host investor conference call today, August 5th, at 8:30am ET --- MIAMI, Aug. 05, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. Recent Business Highlights: Received premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA) for the CGuard Prime carotid stent systemCommenced commercial launch of the CGuard Prime carotid stent system in the U.S. MarketRaised $58 million in gross proceeds from an equity private placement and the exercise of existin

    8/5/25 8:00:00 AM ET
    $NSPR
    Medical/Dental Instruments
    Health Care